Praxis Precision Medicines Terminates Material Agreement

TL;DR

**Praxis Precision Medicines just terminated a key agreement, watch for details on impact.**

AI Summary

Praxis Precision Medicines, Inc. filed an 8-K on January 11, 2024, reporting the termination of a material definitive agreement on January 10, 2024. This termination, while not specified in detail within this filing, indicates a significant change in the company's operational or financial strategy. For investors, this matters because the termination of a key agreement could impact future revenue streams, development pipelines, or strategic partnerships, potentially affecting the stock's valuation.

Why It Matters

The termination of a material agreement can signal a shift in company strategy or financial health, potentially impacting future growth prospects and investor confidence.

Risk Assessment

Risk Level: medium — The filing indicates a significant event (termination of a material agreement) without providing details, creating uncertainty about its financial and operational impact.

Analyst Insight

Investors should monitor for subsequent filings or press releases from Praxis Precision Medicines, Inc. that provide more details about the terminated agreement and its potential impact on the company's operations and financials.

Key Players & Entities

• Praxis Precision Medicines, Inc. (company) — the registrant filing the 8-K
• January 10, 2024 (date) — date of the earliest event reported
• January 11, 2024 (date) — date the 8-K was filed
• 001-39620 (other) — Commission File Number
• PRAX (other) — Trade Symbol for Common Stock

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share PRAX The Nasdaq Glo
• $75 million — ng an aggregate offering price of up to $75 million from time to time through Jefferies, ac
• $9.6 million — gregate gross proceeds of approximately $9.6 million. A copy of the Sales Agreement was fil

Filing Documents

• prax-20240110.htm (8-K) — 30KB
• 0001689548-24-000013.txt ( ) — 155KB
• prax-20240110.xsd (EX-101.SCH) — 2KB
• prax-20240110_lab.xml (EX-101.LAB) — 24KB
• prax-20240110_pre.xml (EX-101.PRE) — 13KB
• prax-20240110_htm.xml (XML) — 3KB

02. Termination of a Material Definitive Agreement

Item 1.02. Termination of a Material Definitive Agreement. As previously disclosed, on December 7, 2023, Praxis Precision Medicines, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC ("Jefferies"), pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $75 million from time to time through Jefferies, acting as the sales agent. On January 10, 2024, the Company delivered written notice to Jefferies to terminate the Sales Agreement pursuant to Section 7(b) thereof, effective immediately. The Company is not subject to any termination penalties related to the termination of the Sales Agreement. Pursuant to the Sales Agreement, the Company has sold an aggregate of 404,643 shares of its common stock for aggregate gross proceeds of approximately $9.6 million. A copy of the Sales Agreement was filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2023 (the "Original Current Report"). The description of the Sales Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 1.1 to the Original Current Report. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRAXIS PRECISION MEDICINES, INC. Date: January 11, 2024 By: /s/ Marcio Souza Marcio Souza Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR